Is mammography for breast cancer screening cost-effective in both western and asian countries?: Results of a systematic review

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4141-4149

  Yoo, Ki Bong ^a,b   Kwon, Jeoung A ^a,b   Cho, Eun ^c   Kang, Moon Hae ^a,b   Nam, Jung Mo ^d   Choi, Kui Son ^e   Kim, Eun Kyung ^b   Choi, Yun Jeong ^a   Park, Eun Cheol ^b,d  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d Department of Preventive Medicine   (South Korea)

^e National Cancer Center   (South Korea)

Author keywords

Asia; Breast cancer; Cost effectiveness; Mammography; Mass screening; Systematic review

Indexed keywords

ARTICLE; ASIA; BREAST TUMOR; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; EUROPE; FEMALE; HUMAN; MAMMOGRAPHY; PROGNOSIS; UNITED KINGDOM; UNITED STATES;

ASIA; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EUROPE; FEMALE; GREAT BRITAIN; HUMANS; MAMMOGRAPHY; PROGNOSIS; UNITED STATES;

EID: 84885459205     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4141     Document Type: Article

References (51)

1. Carles M, Vilaprinyo E, Cots F, et al (2011). Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). BMC Cancer, 11, 192.
2. Carney PA, Miglioretti DL, Yankaskas BC, et al (2003). Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med, 138, 168-75.
3. de Gelder R, Bulliard J-L, de Wolf C, et al (2009). Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer, 45, 127-38.
4. de Koning HJ, Fracheboud J, Boer R, et al (1995). Nation-wide breast cancer screening in The Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for Breast Cancer Screening (NETB). Int J Cancer, 60, 777-80.
5. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al (1991). Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer, 49, 531-7.
6. El-Bastawissi AY, White E, Mandelson MT, Taplin S (2001). Variation in mammographic breast density by race. Ann Epidemiol, 11, 257-63.
7. Evans DG, Warwick J, Astley SM, et al (2012). Assessing individual breast cancer risk within the UK national health service breast screening program: a new paradigm for cancer prevention. Cancer Prev Res (Phila), 5, 943-51.
8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
9. Fracheboud J, de Koning HJ, Beemsterboer PM, et al (1998). Nation-wide breast cancer screening in The Netherlands: results of initial and subsequent screening 1990-1995. National Evaluation Team for Breast Cancer Screening. Int J Cancer, 75, 694-8.
10. Garuz R, ForcenT, Cabases J, et al (1997). Economic evaluation of a mammography-based breast cancer screening programme in Spain. Eur J Public Health, 7, 68-76.
11. Graham-Rowe D (2012). Risk analysis: a dense issue. Nature, 485, 60-1.
12. Green M, Raina V (2008). Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: Current perspectives and important considerations. Asia Pac J Clin Oncol, 4, 5-13.
13. Hardle W (1990). Applied nonparametric regression. Cambridge University Press, UK.
14. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S (2012). Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening? Int J Cancer, 130, 2930-8.
15. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al (2005). The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer, 6, 391-401.
16. Huang CS, Chang KJ, Shen CY (2001). Breast cancer screening in Taiwan and China. Breast Dis, 13, 41-8.
17. IARC (2011). International Agency for Research on Cancer:CI5plus. http://ci5.iarc.fr/CI5plus/ci5plus.htm.
18. Kang MH, Park EC, Choi KS, et al (2013). The national cancer screening program for breast cancer in the republic of korea: is it cost-effective? Asian Pac J Cancer Prev, 14, 2059-65.
19. Kikuchi M, Tsunoda H, Koyama T, et al (2012). Opportunistic breast cancer screening by mammography in Japan for women in their 40s at our preventive medical center: harm or benefit? Breast Cancer, [Epub ahead of print].
20. Kim Y, Jun JK, Choi KS, et al (2011). Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev, 12, 725-30.
21. Knox EG (1988). Evaluation of a proposed breast cancer screening regimen. BMJ, 297, 650-4.
22. Leivo T, Sintonen H, Tuominen R, et al (1999). The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. Cancer, 86, 638-46.
23. Leong SP, Shen ZZ, Liu TJ, et al (2010). Is breast cancer the same disease in Asian and Western countries? 'World J Surg, 34, 2308-24.
24. Leung TK, Huang PJ, Chen CS, et al (2010). Is breast MRI screening more effective than digital mammography in Asian women? J Exp Clin Med, 2, 245-50.
25. Lindfors KK, Rosenquist CJ (1995). The cost-effectiveness of mammographic screening strategies. JAMA, 274, 881-4.
26. Lynge E, Braaten T, Njor SH, et al (2011). Mammography activity in Norway 1983 to 2008. Acta Oncol, 50, 1062-7.
27. Ma GX, Yin L, Gao W, et al (2012). Workplace-based breast cancer screening intervention in china. Cancer Epidemiol Biomarkers Prev, 21 , 358-67.
28. Mandelblatt JS, Cronin KA, Bailey S, et al (2009). Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med, 151, 738-47.
29. Maurice A, Evans DG, Affen J, et al (2012). Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit. Int J Cancer, 131, 417-25.
30. Norum J (1999). Breast cancer screening by mammography in Norway. Is it cost-effective? Ann Oncol, 10, 197-203.
31. Ofman JJ, Sullivan SD, Neumann PJ, et al (2003). Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm, 9, 53-61.
32. Ohuchi N, Suzuki A, Sakurai Y, et al (2009). Current status and problems of breast cancer screening. JMAJ, 52, 45-9.
33. Okonkwo QL, Draisma G, der Kinderen A, et al (2008). Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst, 100, 1290-300.
34. Okubo I, Glick H, Frumkin H, Eisenberg JM (1991). Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer, 67, 2021-9.
35. Olsen AH, Lynge E, Njor SH, et al (2013). Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer, 132, 208-14.
36. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
37. Peterson LE, Goodman C, Karnes EK, et al (2009). Assessment of the quality of cost analysis literature in physical therapy. Phys Ther, 89, 733-55.
38. Rosenquist CJ, Lindfors KK (1998). Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer, 82, 2235-40.
39. Schousboe JT, Kerlikowske K, Loh A, Cummings SR (2011). Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med, 155, 10-20.
40. Shapiro S, Coleman EA, Broeders M, et al (1998). Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European network of pilot projects for breast cancer screening. Int J Epidemiol, 27, 735-42.
41. Stout NK, Rosenberg MA, Trentham-Dietz A, et al (2006). Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst, 98, 774-82.
42. The World Bank (2013). GDP per capita. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
43. Tonelli M, Gorber SC, Joffres M, et al (2011). Recommendations on screening for breast cancer in average-risk women aged 40-74 years. Cmaj, 183, 1991-2001.
44. USPSTF (2009). Screening for breast cancer: US preventive services task force recommendation statement. Ann Intern Med, 151, 716-26.
45. Van der Maas PJ, De Koning HJ, Van Ineveld BM, et al (1989). The cost-effectiveness of breast cancer screening. Int J Cancer, 43, 1055-60.
46. White E, Lee CY, Kristal AR (1990). Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst, 82, 1546-52.
47. WHO. (2001). Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeceonomics and Health. Chaired by Jeffrey D. Sachs, Presented to Gro Harlem Brundtland, Director-General of the World Health Organization, Geneva, Switzerland.
48. Wong IOL, Kuntz KM, Cowling BJ, et al (2010). Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition Markov modelling. Hong Kong Med J, 16, 38-41.
49. Woo PPS, Kim JJ, Leung GM (2007). What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol, 25, 617-24.
50. Yip CH, Smith RA, Anderson BO, et al (2008). Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer, 113, 2244-56.
51. Zheng S, Bai JQ, Li J, et al (2012). The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years. Int J Cancer, 131, 2622-31.